Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

3.250 -0.130 (-3.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Launching Additional Rare Cannabinoids in Response to Inbound Demand
Via CannabisNewsWire
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Launching Additional Rare Cannabinoids in Response to Inbound Demand
Via Investor Brand Network
Topics Supply Chain
InMed Pharmaceuticals Inc. (NASDAQ: INM) Featured in Virtual Coverage of the 34th Annual Roth Conference
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at 34th Annual Roth Conference
Via Investor Brand Network
InMed Pharmaceuticals Expanding Portfolio In Rare Cannabinoid Market
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Expanding Portfolio in Rare Cannabinoid Market
Via Investor Brand Network
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market
Via CannabisNewsWire
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market
Via Investor Brand Network
Topics Supply Chain
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market
Via CannabisNewsWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market
Via Investor Brand Network
InMed's Evolution To Commercial Sales Featured In Research Report
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
InMed’s (NASDAQ: INM) Evolution to Commercial Sales Featured in Research Report
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report
Via Investor Brand Network
InMed Names BayMedica VP Of Sales, Releases Q2 2022 Report
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
InMed (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report
Via Investor Brand Network
Topics Intellectual Property Supply Chain
InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT
LONDON, UK / ACCESSWIRE / February 16, 2022 / InMed Pharmaceuticals' (INM's) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and... 
From Edison Investment Research Limited
Via AccessWire
InMed Positioned To Offer Rare Cannabinoid Manufacturing Technologies
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report
Via Investor Brand Network
Topics Intellectual Property Supply Chain
InMed (NASDAQ: INM) Positioned to Offer Rare Cannabinoid Manufacturing Technologies
Via Investor Brand Network
Topics Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies
Via Investor Brand Network
Topics Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies
Via CannabisNewsWire
Topics Cannabis
InMed Pharmaceuticals To Release Q2 Financial Report, Update
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) to Release Q2 Financial Report, Update
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update
Via Investor Brand Network
InMed Pharmaceuticals Strengthens Leading Role In Rare Cannabinoid Market
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cannabicitran is the first of four new rare cannabinoids InMed... 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition
Via Investor Brand Network
InMed Pharmaceuticals Defining Value Of Rare Cannabinoids In Pharma Space
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Defining Value of Rare Cannabinoids in Pharma Space
Via Investor Brand Network
Topics Cannabis
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.